Table 3.

Pairwise comparison of Kaplan–Meier survival analysis of different PD-1 inhibitors

	Immunotherapy	Camrelizumab		Tislelizumab		Sintilimab		Pembrolizuma b
		Chi-square	P	Chi-square	P	Chi-square	P	Chi-square	P
OS	Camrelizumab			0.111	0.739	< 0.001	0.997	0.001	0.975
	Tislelizumab	0.111	0.739			0.082	0.774	0.086	0.770
	Sintilimab	< 0.001	0.997	0.082	0.774			0.005	0.941
	Pembrolizumab	0.001	0.975	0.086	0.77	0.005	0.941
PFS	Camrelizumab			0.630	0.427	0.439	0.507	1.667	0.197
	Tislelizumab	0.630	0.427			0.045	0.832	0.387	0.534
	Sintilimab	0.439	0.507	0.045	0.832			1.497	0.221
	Pembrolizumab	1.667	0.197	0.387	0.534	1.497	0.221

OS overall survival, PFS progression-free survival